Genomic sequence analysis of a key residue (Arg183) in human G alpha q in invasive non-functional pituitary adenomas
- PMID: 9302401
- DOI: 10.1046/j.1365-2265.1997.2891088.x
Genomic sequence analysis of a key residue (Arg183) in human G alpha q in invasive non-functional pituitary adenomas
Abstract
Objective: With isolated exceptions the only oncogene significantly associated with pituitary tumours is a constitutively active Gs protein (G alpha s). The recent cloning of the cDNA of human G alpha q has facilitated the study of this activator of the phospholipase C beta/Ca2+/ protein kinase C pathway. Since, with isolated exceptions, non-functional tumours are responsive in vitro to TRH and GnRH which activate Gq, we have investigated the genomic sequence of G alpha q, in non-functional (NF) invasive pituitary adenomas, at a residue corresponding to the one most frequently mutated in G alpha s.
Patients and measurements: We studied 27 invasive NF pituitary tumours by direct sequencing of DNA derived from archival slide extracted tumour cells. Primers were designed to encompass Arg183 (corresponding to Arg201 of G alpha s) which when mutated has been shown to have oncogenic potential when transfected into cultural rat fibroblasts. In a previous study we have described allelic loss at tumour suppressor gene loci (TSG) in 7 of these 27 tumours.
Results: We successfully amplified genomic DNA with primers designed from the cDNA sequence of G alpha q with specific exclusion of a processed pseudogene. No mutations were found at Arg183, in either the tumours showing allelic losses at specific TSG loci, or in the 20 remaining tumours in which we found no losses at the TSG loci investigated.
Conclusions: Mutations at this key residue in G alpha q occur infrequently, if at all, in invasive non-functional pituitary tumours. However we cannot exclude the possibility of mutation(s) at the other key residue of G alpha q, Gin209, implicated in GTP hydrolysis, or in other components of this pathway.
Similar articles
-
Pituitary adenomas: screening for G alpha q mutations.J Clin Endocrinol Metab. 1997 Dec;82(12):4184-8. doi: 10.1210/jcem.82.12.4436. J Clin Endocrinol Metab. 1997. PMID: 9398737
-
Screening of candidate oncogenes in human thyrotroph tumors: absence of activating mutations of the G alpha q, G alpha 11, G alpha s, or thyrotropin-releasing hormone receptor genes.J Clin Endocrinol Metab. 1996 Mar;81(3):1134-40. doi: 10.1210/jcem.81.3.8772588. J Clin Endocrinol Metab. 1996. PMID: 8772588
-
Gs alpha and Gi2 alpha mutations in clinically non-functioning pituitary tumours.Clin Endocrinol (Oxf). 1994 Dec;41(6):815-20. doi: 10.1111/j.1365-2265.1994.tb02798.x. Clin Endocrinol (Oxf). 1994. PMID: 7889619
-
G protein abnormalities in pituitary adenomas.Mol Cell Endocrinol. 1998 Jul 25;142(1-2):1-14. doi: 10.1016/s0303-7207(98)00116-6. Mol Cell Endocrinol. 1998. PMID: 9783897 Review.
-
GTPase-inhibiting mutations activate the alpha-chain of Gs in human tumours.Biochem Soc Symp. 1990;56:165-70. Biochem Soc Symp. 1990. PMID: 2124121 Review.
Cited by
-
Invasive pituitary adenomas: significance of proliferation parameters.Pituitary. 1999 Aug;2(2):117-22. doi: 10.1023/a:1009931413106. Pituitary. 1999. PMID: 11081161
-
Pituitary carcinoma with endolymphatic sac metastasis.Pituitary. 2014 Jun;17(3):210-3. doi: 10.1007/s11102-013-0489-x. Pituitary. 2014. PMID: 23645293
-
Pathogenesis of prolactinomas.Pituitary. 2005;8(1):7-15. doi: 10.1007/s11102-005-5080-7. Pituitary. 2005. PMID: 16411063 Review.
-
Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine.EPMA J. 2022 Feb 17;13(1):9-37. doi: 10.1007/s13167-022-00274-5. eCollection 2022 Mar. EPMA J. 2022. PMID: 35273657 Free PMC article. Review.
-
Malignant pituitary tumours.Pituitary. 1998 Apr;1(1):69-81. doi: 10.1023/a:1009975009924. Pituitary. 1998. PMID: 11081185 Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous